The effect of immobilization of heparin and bone morphogenic protein-2 (BMP-2) to titanium surfaces on inflammation and osteoblast function

Biomaterials

Volumn 32, Issue 2, 2011, Pages 366-373

  Kim, Sung Eun ^a   Song, Sang Hun ^b   Yun, Young Pil ^a   Choi, Byung Joon ^b   Kwon, Il Keun ^b   Bae, Min Soo ^b   Moon, Ho Jin ^b   Kwon, Yong Dae ^b  

^a Korea University College of Medicine   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

Bone morphogenic protein 2 (BMP 2); Heparin; Inflammation; Osteoblasts; Peri implantitis; Titanium

Indexed keywords

3-AMINOPROPYLTRIETHOXYSILANE; ALKALINE PHOSPHATE; ANTI-INFLAMMATORY EFFECTS; BIOLOGIC FUNCTIONS; BIOLOGICAL ACTIVITIES; BONE MORPHOGENIC PROTEIN; CALCIUM DEPOSITION; FUNCTIONALIZED; HEPARIN; INFLAMMATION; INFLAMMATORY RESPONSE; OSTEOBLAST FUNCTION; PERI-IMPLANTITIS; PROTEIN ADSORPTION; RHBMP-2; TITANIUM SURFACES; TRANSCRIPT LEVEL; WATER CONTACT ANGLE; XPS;

ADSORPTION; BONE; CELL PROLIFERATION; CONTACT ANGLE; GRAFTING (CHEMICAL); OSTEOBLASTS; PATHOLOGY; PROTEINS; SILICON COMPOUNDS; TITANIUM; X RAY PHOTOELECTRON SPECTROSCOPY;

POLYSACCHARIDES;

3 AMINOPROPYLTRIETHOXYSILANE; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; HEPARIN; INTERLEUKIN 6; TITANIUM; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CELL ASSAY; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDROPHILICITY; INFLAMMATION; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN IMMOBILIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURFACE PROPERTY; X RAY PHOTOELECTRON SPECTROSCOPY;

ALKALINE PHOSPHATASE; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CALCIUM; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; HEPARIN; HUMANS; INTERLEUKIN-6; MACROPHAGES; MICE; MICROSCOPY, ELECTRON, SCANNING; NIH 3T3 CELLS; OSTEOBLASTS; PHOTOELECTRON SPECTROSCOPY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TITANIUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78449243961     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.09.008     Document Type: Article

References (38)

1. Piskounova S., Forsgren J., Brohede U., Engqvist H., Stromme M. In vitro characterization of bioactive titanium dioxide/hydroxyapatite surfaces functionalized with BMP-2. J Biomed Mater Res B Appl Biomater 2009, 91:780-787.
2. Shi Z., Neoh K.G., Kang E.T., Poh C.K., Wang W. Surface functionalization of titanium with carboxymethyl chitosan and immobilized bone morphogenetic protein-2 for enhanced osseointegration. Biomacromolecules 2009, 10:1603-1611.
3. Miron R.J., Oates C.J., Molenberg A., Dard M., Hamilton D.W. The effect of enamel matrix proteins on the spreading, proliferation and differentiation of osteoblasts cultured on titanium surfaces. Biomaterials 2010, 31:449-460.
4. Michael J., Schonzart L., Israel I., Beutner R., Scharnweber D., Worch H., et al. Oligonucleotide-RGD peptide conjugates for surface modification of titanium implants and improvement of osteoblast adhesion. Bioconjug Chem 2009, 20:710-718.
5. Oya K., Tanaka Y., Saito H., Kurashima K., Nogi K., Tsutsumi H., et al. Calcification by MC3T3-E1 cells on RGD peptide immobilized on titanium through electrodeposited PEG. Biomaterials 2009, 30:1281-1286.
6. Balasundaram G., Webster T.J. Increased osteoblast adhesion on nanograined Ti modified with KRSR. J Biomed Mater Res A 2007, 80:602-611.
7. Wang E.A., Rosen V., D'Alessandro J.S., Bauduy M., Cordes P., Harada T., et al. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci U S A 1990, 87:2220-2224.
8. Cook S.D., Wolfe M.W., Salkeld S.L., Rueger D.C. Effect of recombinant human osteogenic protein-1 on healing of segmental defects in non-human primates. J Bone Jt Surg Am 1995, 77:734-750.
9. Kim S.E., Jeon O., Lee J.B., Bae M.S., Chun H.J., Moon S.H., et al. Enhancement of ectopic bone formation by bone morphogenetic protein-2 delivery using heparin-conjugated PLGA nanoparticles with transplantation of bone marrow-derived mesenchymal stem cells. J Biomed Sci 2008, 15:771-777.
10. Govender S., Csimma C., Genant H.K., Valentin-Opran A., Amit Y., Arbel R., et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Jt Surg Am 2002, 84-A:2123-2134.
11. Sellers R.S., Zhang R., Glasson S.S., Kim H.D., Peluso D., D'Augusta D.A., et al. Repair of articular cartilage defects one year after treatment with recombinant human bone morphogenetic protein-2 (rhBMP-2). J Bone Jt Surg Am 2000, 82:151-160.
12. Bax B.E., Wozney J.M., Ashhurst D.E. Bone morphogenetic protein-2 increases the rate of callus formation after fracture of the rabbit tibia. Calcif Tissue Int 1999, 65:83-89.
13. Sheehan J.P., Kallmes D.F., Sheehan J.M., Jane J.A., Fergus A.H., diPierro C.G., et al. Molecular methods of enhancing lumbar spine fusion. Neurosurgery 1996, 39:548-554.
14. King G.N., King N., Cruchley A.T., Wozney J.M., Hughes F.J. Recombinant human bone morphogenetic protein-2 promotes wound healing in rat periodontal fenestration defects. J Dent Res 1997, 76:1460-1470.
15. Sellers R.S., Peluso D., Morris E.A. The effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) on the healing of full-thickness defects of articular cartilage. J Bone Jt Surg Am 1997, 79:1452-1463.
16. Zellin G., Linde A. Importance of delivery systems for growth-stimulatory factors in combination with osteopromotive membranes. An experimental study using rhBMP-2 in rat mandibular defects. J Biomed Mater Res 1997, 35:181-190.
17. Kim J., Park Y., Tae G., Lee K.B., Hwang C.M., Hwang S.J., et al. Characterization of low-molecular-weight hyaluronic acid-based hydrogel and differential stem cell responses in the hydrogel microenvironments. J Biomed Mater Res A 2009, 88:967-975.
18. Kim J., Kim I.S., Cho T.H., Lee K.B., Hwang S.J., Tae G., et al. Bone regeneration using hyaluronic acid-based hydrogel with bone morphogenic protein-2 and human mesenchymal stem cells. Biomaterials 2007, 28:1830-1837.
19. Lee T.C., Ho J.T., Hung K.S., Chen W.F., Chung Y.H., Yang Y.L. Bone morphogenetic protein gene therapy using a fibrin scaffold for a rabbit spinal-fusion experiment. Neurosurgery 2006, 58:373-380.
20. Jeon O., Song S.J., Yang H.S., Bhang S.H., Kang S.W., Sung M.A., et al. Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery. Biochem Biophys Res Commun 2008, 369:774-780.
21. Sasisekharan R., Ernst S., Venkataraman G. On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans. Angiogenesis 1997, 1:45-54.
22. Perets A., Baruch Y., Weisbuch F., Shoshany G., Neufeld G., Cohen S. Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. J Biomed Mater Res A 2003, 65:489-497.
23. Ishibe T., Goto T., Kodama T., Miyazaki T., Kobayashi S., Takahashi T. Bone formation on apatite-coated titanium with incorporated BMP-2/heparin in vivo. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009, 108:867-875.
24. Young E. The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008, 122:743-752.
25. Manduteanu I., Voinea M., Antohe F., Dragomir E., Capraru M., Radulescu L., et al. Effect of enoxaparin on high glucose-induced activation of endothelial cells. Eur J Pharmacol 2003, 477:269-276.
26. Shields L.B., Raque G.H., Glassman S.D., Campbell M., Vitaz T., Harpring J., et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine (Phila Pa 1976) 2006, 31:542-547.
27. Ho Y.C., Mi F.L., Sung H.W., Kuo P.L. Heparin-functionalized chitosan-alginate scaffolds for controlled release of growth factor. Int J Pharm 2009, 376:69-75.
28. Lin H., Zhao Y., Sun W., Chen B., Zhang J., Zhao W., et al. The effect of crosslinking heparin to demineralized bone matrix on mechanical strength and specific binding to human bone morphogenetic protein-2. Biomaterials 2008, 29:1189-1197.
29. Chung H.J., Kim H.K., Yoon J.J., Park T.G. Heparin immobilized porous PLGA microspheres for angiogenic growth factor delivery. Pharm Res 2006, 23:1835-1841.
30. Shi Z., Neoh K.G., Kang E.T., Poh C., Wang W. Titanium with surface-grafted dextran and immobilized bone morphogenetic protein-2 for inhibition of bacterial adhesion and enhancement of osteoblast functions. Tissue Eng Part A 2009, 15:417-426.
31. Park Y.J., Kim K.H., Lee J.Y., Ku Y., Lee S.J., Min B.M., et al. Immobilization of bone morphogenetic protein-2 on a nanofibrous chitosan membrane for enhanced guided bone regeneration. Biotechnol Appl Biochem 2006, 43:17-24.
32. Turksen K., Bhargava U., Moe H.K., Aubin J.E. Isolation of monoclonal antibodies recognizing rat bone-associated molecules in vitro and in vivo. J Histochem Cytochem 1992, 40:1339-1352.
33. van den Beucken J.J., Walboomers X.F., Boerman O.C., Vos M.R., Sommerdijk N.A., Hayakawa T., et al. Functionalization of multilayered DNA-coatings with bone morphogenetic protein 2. J Control Release 2006, 113:63-72.
34. Bancroft G.N., Sikavitsas V.I., van den Dolder J., Sheffield T.L., Ambrose C.G., Jansen J.A., et al. Fluid flow increases mineralized matrix deposition in 3D perfusion culture of marrow stromal osteoblasts in a dose-dependent manner. Proc Natl Acad Sci U S A 2002, 99:12600-12605.
35. Thourani V.H., Brar S.S., Kennedy T.P., Thornton L.R., Watts J.A., Ronson R.S., et al. Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2000, 278:H2084-H2093.
36. Hochart H., Jenkins P.V., Smith O.P., White B. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol 2006, 133:62-67.
37. Berglundh T., Persson L., Klinge B. A systematic review of the incidence of biological and technical complications in implant dentistry reported in prospective longitudinal studies of at least 5 years. J Clin Periodontol 2002, 29(Suppl. 3):197-212. discussion 232-193.
38. Kwon Y.D., Karbach J., Wagner W., Al-Nawas B. Peri-implant parameters in head and neck reconstruction: influence of extraoral skin or intraoral mucosa. Clin Oral Implants Res 2010, 21:316-320.